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Aims In the DAPA-HF trial, the SGLT2 inhibitor dapagliflozin reduced the risk of worsening heart failure (HF) and death





In this post hoc analysis, we examined the effect of study treatment in the following yes/no subgroups: diuretic, di-
goxin, mineralocorticoid receptor antagonist (MRA), sacubitril/valsartan, ivabradine, implanted cardioverter-
defibrillating (ICD) device, and cardiac resynchronization therapy. We also examined the effect of study drug
according to angiotensin-converting enzyme inhibitor/angiotensin receptor blocker dose, beta-blocker (BB) dose,
and MRA (>_50% and <50% of target dose). We analysed the primary composite endpoint of cardiovascular death
or a worsening HF event. Most randomized patients (n= 4744) were treated with a diuretic (84%), renin–angioten-
sin system (RAS) blocker (94%), and BB (96%); 52% of those taking a BB and 38% taking a RAS blocker were
treated with >_50% of the recommended dose. Overall, the dapagliflozin vs. placebo hazard ratio (HR) was 0.74
[95% confidence interval (CI) 0.65–0.85] for the primary composite endpoint (P< 0.0001). The effect of dapagliflo-
zin was consistent across all subgroups examined: the HR ranged from 0.57 to 0.86 for primary endpoint, with no
significant randomized treatment-by-subgroup interaction. For example, the HR in patients taking a RAS blocker,
BB, and MRA at baseline was 0.72 (95% CI 0.61–0.86) compared with 0.77 (95% CI 0.63–0.94) in those not on all
three of these treatments (P-interaction 0.64).
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Conclusion The benefit of dapagliflozin was consistent regardless of background therapy for HF.
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Introduction
In the placebo-controlled Dapagliflozin And Prevention of Adverse-
outcomes in Heart Failure (DAPA-HF) trial, the sodium–glucose
cotransporter 2 inhibitor (SGLT2i) dapagliflozin reduced the risk of
heart failure (HF) hospitalization and mortality, and improved symp-
toms, in 4744 patients with HF and reduced ejection fraction
(HFrEF).1,2 It is clearly important to know whether these effects
were truly additive to the benefits obtained from other evidence-
based treatments in HFrEF. Therefore, in this post hoc analysis, we
examined outcomes in patients randomized to dapagliflozin, vs. pla-
cebo, according to background drug and device therapy. Because
>90% of patients were receiving each of a renin–angiotensin system
(RAS) blocker and beta-blocker (BB) at baseline, we examined the ef-
fect of dapagliflozin added to a higher or lower dose of these treat-
ments. For other therapies, including a mineralocorticoid receptor
antagonists (MRAs), digoxin and devices, we examined outcomes
according to whether the treatment was taken at baseline or not.
We also examined the effect of dapagliflozin in patients receiving
combination therapy.
Methods
The design and results of DAPA-HF are published.1,2 Briefly, DAPA-HF
was a prospective, randomized, double-blind, placebo-controlled trial in
patients with HFrEF, which evaluated the efficacy and safety of dapagliflo-
zin 10 mg once daily, compared with matching placebo, added to standard
care. Ethics committees at each of the 410 participating institutions (in 20
countries) approved the protocol, and all patients gave written informed
consent.
Study patients
Men and women aged >_18 years with HF were eligible if they were in
New York Heart Association (NYHA) functional Class II–IV, had a left
ventricular ejection fraction (LVEF) <_40%, and, in the view of the investi-
gator, were optimally treated with pharmacological and device therapy
for HFrEF, according to local guidelines. The protocol advised that an
angiotensin-converting enzyme (ACE) inhibitor, or angiotensin receptor
blocker (ARB) or sacubitril/valsartan and a BB, as well as an MRA, should
be used at guideline-recommended doses, unless contraindicated or not
tolerated.
Participants were also required to have an N-terminal pro-B-type
natriuretic peptide (NT-proBNP) concentration >_600 pg/mL (>_400 pg/
mL if hospitalized for HF within the previous 12 months). Patients with
atrial fibrillation or atrial flutter were required to have an NT-proBNP
level >_900 pg/mL, irrespective of history of HF hospitalization. Key exclu-
sion criteria included: symptoms of hypotension or systolic blood pres-
sure <95 mmHg, estimated glomerular filtration rate (eGFR) <30 mL/
min/1.73 m2 (or rapidly declining renal function), Type 1 diabetes mellitus,
and another condition likely to prevent patient participation in the trial or
greatly limit life expectancy. A full list of exclusion criteria is provided in
the design paper.1
Trial outcomes
The primary outcome was the composite of an episode of worsening HF
or cardiovascular (CV) death, whichever occurred first. An episode of
worsening HF was either an unplanned hospitalization or an urgent visit
resulting in intravenous therapy for HF. Secondary endpoints included
the composite of the occurrence of HF hospitalization or CV death. All-
cause mortality was a prespecified secondary endpoint. For the purposes
of this analysis, we examined the effect of dapagliflozin, compared to pla-
cebo, on the primary composite outcome and the individual component
of CV death.
Background treatment subgroups
In this post hoc analysis, we compared the effect of dapagliflozin with pla-
cebo in subgroups of patients treated with other background pharmaco-
logical and device therapies. Subgroups were limited to those with >200
individuals to minimize the likelihood of a Type 1 error.3,4 Therefore, the
yes/no groups which were analysed, included diuretic, digitalis glycosides
(hereafter referred to as digoxin), MRA, sacubitril/valsartan, ivabradine,
defibrillating device [implantable cardioverter-defibrillator or cardiac
resynchronization therapy plus defibrillator (CRT-D)] and CRT (CRT-P
and CRT-D). Because so few patients not taking a BB or a RAS blocker,
we analysed the effect of study drug according to BB and RAS blocker
dose at baseline, defined as >_50% target dose and <50% of target dose.
We also examined the treatment effect in patients receiving >_50 and
<50% of target MRA dose. Target daily doses were taken from contem-
porary guidelines5,6 and included: carvedilol 50 mg, bisoprolol 10 mg,
metoprolol succinate 200 mg, metoprolol tartrate 200 mg, and nebivolol
10 mg; patients (n= 85) taking other b-blockers were classified as taking
<50% target dose. Target daily doses for ACE inhibitors and ARB were
captopril 150 mg, enalapril 40 mg, fosinopril 40 mg, lisinopril 35 mg, peri-
ndopril 16 mg, quinapril 40 mg, ramipril 10 mg, trandolapril 4 mg, cande-
sartan 32 mg, losartan 150 mg, valsartan 320 mg, and irbesartan 300 mg;
patients (n= 315) taking other ACE inhibitors/ARB were classified as tak-
ing <50% target dose. The target doses of MRA were defined as either
eplerenone or spironolactone 50 mg daily. For the purposes of this ana-
lysis, MRAs were not classified as a diuretic and sacubitril/valsartan was
not included in the analysis of dose of ACE inhibitor/ARB.
Statistical analysis
Baseline characteristics were compared between groups by using the
Kruskal–Wallis test for continuous variables and the v2 test for categoric-
al variables. The effect of dapagliflozin compared to placebo on each out-
come was examined by means of hazard ratio (HR) and 95% confidence
intervals (CIs) derived from Cox proportional-hazards models, stratified
according to diabetes status and adjusted for a history of hospitalization
for HF and treatment-group assignment. We analysed the effect of dapa-
gliflozin compared to placebo on the proportion of patients (presented
as an odds ratio) who reported a clinically significant (>_5 point) improve-
ment or deterioration in the Kansas City Cardiomyopathy Questionnaire
(KCCQ) Total Symptom Score (TSS) at 8 months following






























































































randomization using previously described methods.7 Change in systolic
blood pressure and serum creatinine was analysed using a mixed model
for repeated measurements (adjusted for baseline values, visit, random-
ized treatment and interaction of treatment, and visit with a random
intercept and slope per patient). The least-squares mean differences be-
tween treatment groups are presented by subgroup with 95% CI.
Prespecified adverse events of interest (volume depletion and renal ad-
verse events) were analysed in patients who were randomized and
received at least one dose of dapagliflozin or placebo. All analyses were
performed using Stata version 16 (College Station, TX, USA) and SAS,
version 9.4 (SAS institute). A P-value <0.05 was considered statistically
significant.
Results
Most patients in DAPA-HF were treated with a diuretic (84%), RAS
blocker (94%), and BB (96%). Of patients taking a RAS blocker
(n= 3952), 1517 patients (38%) were treated with >_50% of a
guideline-recommended target dose. Of those taking a BB (n= 4558),
2349 patients (52%) were treated with >_50% of the guideline-
recommended dose of an evidence-based drug. Overall, 71% of
patients were treated with an MRA, 19% with digoxin, 26% with a de-
fibrillator, and 7% had a CRT device. The majority of patients (96%)
were treated with at least two of an ACE inhibitor/ARB/ARNI, a BB
and/or an MRA, with 3091 (65%) patients on all three of these classes
of drugs (Supplementary material online, Figure S1).
Baseline characteristics according to
background therapy
Table 1 shows the background characteristics in all randomized
patients and by background therapy and Table 2 shows the character-
istics by combinations of background therapy. Compared with the
overall DAPA-HF population, patients treated with digoxin had a
lower LVEF, and, compared to other treatment subgroups, the worst
NYHA functional class distribution, worst symptoms [as measured
by the Kansas City Cardiomyopathy Questionnaire (KCCQ) Total
Symptom Score (TSS)], highest NT-proBNP level and greatest fre-
quency of prior HF hospitalization and atrial fibrillation. Excepting
atrial fibrillation, similar trends were seen for patients treated with
diuretics and an MRA, although both the latter groups also had worse
renal function than the overall DAPA-HF population (especially
patients treated with diuretics). Patients receiving sacubitril/valsartan
were more likely to have an implanted device (ICD and/or CRT), and
a lower mean LVEF and median NT-proBNP level, than the overall
population. Patients receiving ivabradine were less likely to be taking
a BB or to have atrial fibrillation than the overall DAPA-HF
population.
Patients receiving >_50% of target RAS blocker dose had a higher
systolic blood pressure and lower median NT-proBNP level and
KCCQ-TSS than patients in the overall DAPA-HF population. Other
than a lower KCCQ-TSS, there were no major differences between
patients taking >_50% of target dose BB than in the overall DAPA-HF
population.
Among patients with a device, fewer were women (especially an
ICD) and patients with a device were generally older than in the
overall DAPA-HF population; they also had a worse KCCQ-TSS and
lower LVEF. CRT patients had a higher median NT-proBNP level,
worse renal function and were more likely to have been hospitalized
for HF previously, compared to the overall population.
Effect of dapagliflozin according to
background therapy
Supplementary material online, Figure S2 shows the cumulative inci-
dence of the primary endpoint in the major treatment subgroups of
interest. The HRs for the effect of dapagliflozin, compared with pla-
cebo, for the primary composite outcome and CV death, according
to background therapy are summarized in Figures 1 and 2, respective-
ly. The benefit of dapagliflozin over placebo was consistent across all
treatment subgroups, including diuretic, digoxin, MRA, sacubitril/val-
sartan, ivabradine, and devices (ICD or CRT), without any significant
interaction between background therapy and the effect of random-
ized therapy on the primary composite outcome (Figure 1) or CV
death (Figure 2).
We also examined the effect of dapagliflozin, compared with pla-
cebo, according to background ACE inhibitor/ARB, BB and MRA
dose. The effect of dapagliflozin, vs. placebo, was the same in patients
treated with >_50% of target doses of these drugs, compared with
those treated with a lower dose (Figures 1 and 2).
Effect of dapagliflozin according to
combinations of treatment
Figures 2 and 3, respectively, summarize the HRs for dapagliflozin,
compared with placebo, for CV death and the primary composite
outcome, according to various combinations of background therapy.
The beneficial effect of dapagliflozin was consistent regardless of
whether patients were treated with the combination of a RAS-
blocker, BB and MRA, or were not on all three of these treatments at
baseline. Neither the combination of an ICD and >_50% of target
dose of both an RAS blocker and BB, nor an MRA with >_50% of tar-
get dose of both an RAS blocker and BB, modified the response to
dapagliflozin (Figures 2 and 3). A small proportion of patients (7%)
were on ‘quadruple-therapy’ at baseline with a combined angiotensin
receptor neprilysin inhibitor (sacubitril/valsartan), a BB and an MRA;
the benefit of dapagliflozin was consistent in this subgroup with no
significant interaction when compared with participants not receiving
‘quadruple-therapy’.
Effect of dapagliflozin on symptom
frequency and severity according to
background therapy
A significantly greater proportion of patients randomized to dapagli-
flozin compared to placebo self-reported a clinically significant im-
provement (>_5 point increase) in the KCCQ-TSS at 8 months
following randomization and significantly fewer dapagliflozin patients
reported a meaningful deterioration (>_5 point decrease) compared
to placebo (Table 3). This effect was consistent across all subgroups
of background therapy and combinations analysed.




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Effect of dapagliflozin on change in
systolic blood pressure and serum
creatinine according to background
therapy
Compared with placebo, dapagliflozin reduced blood pressure at 8
months following randomization with no significant treatment effect
modification observed by individual background therapy or their
combinations (Table 3). The small increase in serum creatinine
observed with dapagliflozin compared to placebo at 8 months was
similar among the subgroups analysed (Table 3).
Effect of dapagliflozin on volume
depletion or renal adverse events
according to background therapy
In patients treated with a diuretic, adverse events related to volume
depletion occurred more frequently with dapagliflozin compared to
placebo, with fewer events seen in those not on a diuretic and
randomized to dapagliflozin (Table 4). A similar pattern was observed
in those treated with >_50% of target MRA dose, the combination of
an RAS blocker, BB, and MRA, and combinations including >_50% of
both RAS blocker and BB target dose (Table 4). Renal adverse events
were less common with dapagliflozin compared to placebo in those
not on a diuretic at baseline with no difference in those treated with
a diuretic (Table 4). Patients treated with >_50% of target RAS blocker
dose more frequently had a renal adverse event with dapagliflozin
compared to placebo than those on <50% target dose with the same
pattern in those on combinations of therapy that include >_50% of
target RAS blocker dose.
Discussion
When new treatments are shown to improve outcomes in HFrEF, a
key question is whether the benefit is truly incremental, i.e. clearly
   No (n=4390)
   Yes (n=354)
CRTb
   No (n=3502)
   Yes (n=1242)
ICDa
   ≥50% (n=2953)
   <50% (n=417)
MRA target dose
   ≥50% (n=2349)
   <50% (n=2209)
Beta-blocker target dose
   ≥50% (n=1517)
   <50% (n=2435)
ACEi/ARB target dose
   No (n=4236)
   Yes (n=508)
ARNI
   No (n=4516)
   Yes (n=228)
Ivabradine
   No (n=3857)
   Yes (n=887)
Digoxin
   No (n=1374)
   Yes (n=3370)
MRA
   No (n=736)















































































0.25 0.50 0.75 1.00 1.251.50
Dapagliflozin better Placebo better
Figure 1 Effect of dapagliflozin compared to placebo on the primary composite outcome by background heart failure therapy. The primary out-
come was a composite of worsening heart failure (hospitalization or an urgent visit resulting in intravenous therapy for heart failure) or death from
cardiovascular causes. Hazard ratios and 95% confidence intervals were estimated with the use of Cox regression models, stratified according to dia-
betes status, with a history of hospitalization for heart failure, and treatment-group assignment as explanatory variables. ACEi, angiotensin-converting
enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; CI, confidence interval; CRT, cardiac resynch-
ronization therapy; ICD, implantable cardioverter-defibrillator; MRA, mineralocorticoid receptor antagonist. aICD or cardiac resynchronization ther-
apy with defibrillator. bCardiac resynchronization therapy with or without a defibrillator.
































additive to the benefits of established treatments. There is no dispute
that the three core pharmacological therapies for HFrEF are an RAS
blocker (ACE inhibitor/ARB), BB and MRA, based on at least two
randomized trials showing each of these treatments reduced mortal-
ity and hospitalization, and in the case of BBs and MRAs, even when
these treatments were added to an RAS blocker (and in the case of
an MRA, added to a BB also).8–15 Over the past decade, three new
pharmacological approaches have demonstrated additional benefit
when added to these core therapies. The first was the sinus node in-
hibitor, ivabradine, followed by the neprilysin inhibitor sacubitril and
most recently, the SGLT2 inhibitor, dapagliflozin.2,16,17 In the present
report, we have shown that dapagliflozin not only improves out-
comes when added to the core combination of RAS blocker, BB and
MRA but also had a consistent benefit whether background therapy
included either ivabradine or sacubitril/valsartan or not. The demon-
stration that neither of these agents modified the response to
dapagliflozin supports the view that SGLT2 inhibition acts in a mech-
anistically independent and complementary way to other therapies
for HFrEF. Initially considered to be glucose-lowering medications
for the management of Type 2 diabetes mellitus, the finding in
DAPA-HF that the benefit of dapagliflozin occurred in patients both
with, and without diabetes, suggests that this benefit is independent
of any glucose-lowering effect.2 Various theories as to the mecha-
nisms of action behind the benefits of dapagliflozin have been pro-
posed, including a diuretic effect, an increase in renal erythropoietin
secretion, reduction in myocardial fibrosis, along with potential
effects on the peripheral vasculature, ion transporters, adipokines,
and sympathetic nervous system activity.18
We also attempted to address further questions that are often
raised in discussions about the treatment of HFrEF.
One such question relates to dosing of background pharmaco-
logical therapy. The evidence-based target doses of certain RAS
Overall Effect (n=4744)
Diuretic
   Yes (n=4008)
   No (n=736)
MRA
   Yes (n=3370)
   No (n=1374)
Digoxin
   Yes (n=887)
   No (n=3857)
ARNI
   Yes (n=508)
   No (n=4236)
Ivabradine
   Yes (n=228)
   No (n=4516)
ACEi/ARB target dose
   <50% (n=2435)
   ≥50% (n=1517)
Beta-blocker target dose
   <50% (n=2209)
   ≥50% (n=2349)
MRA target dose
  <50% (n=417)
   ≥50% (n=2953)
ICDa
   Yes (n=1242)
   No (n=3502)
CRTb
   Yes (n=354)
   No (n=4390)
ACEi/ARB + beta-blocker + MRA
   Yes (n=2765)
   No (n=1979)
ACEi/ARB ≥50% target dose + beta-blocker ≥50% target dose 
   Yes (n=975)
   No (n=3769)
ACEi/ARB ≥50% target dose + beta-blocker ≥50% target dose + MRA
  Yes (n=711)
   No (n=4033)
ACEi/ARB ≥50% target dose + beta-blocker ≥50% target dose + ICDa
   Yes (n=244)
   No (n=4500)
ARNI + beta-blocker + MRA
   Yes (n=332)














































































































0.25 0.50 0.75 1.00 1.25 1.50
Dapagliflozin better Placebo better
227/2373 (9.6%) 273/2371 (11.5%)
Figure 2 Effect of dapagliflozin compared to placebo on cardiovascular death by background heart failure therapy. Hazard ratios and 95% confi-
dence intervals were estimated with the use of Cox regression models, stratified according to diabetes status, with a history of hospitalization for
heart failure, and treatment-group assignment as explanatory variables. ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor
blocker; ARNI, angiotensin receptor neprilysin inhibitor; CI, confidence interval; CRT, cardiac resynchronization therapy; ICD, implantable cardi-
overter-defibrillator; MRA, mineralocorticoid receptor antagonist. aICD or cardiac resynchronization therapy with defibrillator. bCardiac resynchro-
nization therapy with or without a defibrillator.




















































..inhibitors and BBs are well defined and there is evidence of a dose-
response for RAS inhibitors, at least in terms of reduction in HF hos-
pitalization.19,20 Yet registry studies repeatedly show that these
evidence-based target doses are infrequently achieved in clinical prac-
tice and it is not always clear that this is because of intolerance of
higher doses.21,22 Consequently, it is possible that the incremental
benefit of a new treatment might be less if the dosing of conventional
treatments was optimized. To address this issue, we also examined
the effectiveness of dapagliflozin according to background dose of
both RAS blockers, BBs and MRAs, demonstrating consistent benefit
irrespective of whether patients were taking higher (>_50% guideline
target) or lower (<50%) doses of these drugs.
Device therapy also plays an important role in the management of
HFrEF, but as with drug dosing, ‘real world’ studies show devices are
underutilized in practice, with substantial geographical variation in
rates of use, suggesting the influence of economic factors, among
others, in explaining this variance.23–25 We also examined the incre-
mental efficacy of dapagliflozin in patients with an implanted defibril-
lating device and in those with CRT. Again, we found a consistent
benefit in patients with either type of device, with no evidence that
background device therapy modified the response to dapagliflozin.
Lastly, although its use is declining, digoxin was shown in a large
randomized trial to reduce hospitalization rates when added to an
ACE inhibitor in patients with HFrEF.26 Therefore, we also examined
the effect of adding dapagliflozin to digoxin and once more found a
consistent benefit according to whether background therapy
included digoxin or not.
As with all analyses like these, there are limitations. Most of these
subgroups were not pre-specified. Despite requiring each subgroup
to include >200 patients, such analyses are inherently underpowered.
We had too few patients treated with the combination of hydralazine
and isosorbide dinitrate to perform a meaningful analysis.
In summary, we found a consistent benefit of dapagliflozin, over
placebo, regardless of background drug and device therapy. These
findings suggest that the effects of dapagliflozin are incremental and
complementary to conventional therapies for HFrEF.
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Overall Effect (n=4744)
ACEi/ARB + beta-blocker + MRA
   Yes (n=2765)
   No (n=1979)
ACEi/ARB ≥50% target dose + beta-blocker ≥50% target dose
   Yes (n=975)
   No (n=3769)
ACEi/ARB ≥50% target dose + beta-blocker ≥50% target dose + MRA
   Yes (n=711)
   No (n=4033)
ACEi/ARB ≥50% target dose + beta-blocker ≥50% target dose + ICDa
   Yes (n=244)
   No (n=4500)
ARNI + beta-blocker + MRA     
   Yes (n=332)
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Figure 3 Effect of dapagliflozin compared to placebo on the primary composite outcome by combinations of background heart failure therapy. ACEi,
angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; CI, confidence interval;
ICD, implantable cardioverter-defibrillator; MRA, mineralocorticoid receptor antagonist. aICD or cardiac resynchronization therapy with defibrillator.
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Table 4 Volume depletion or renal adverse events by randomized treatment and background heart failure therapy






Yes 162/1999 (8.1) 131/2004 (6.5) 0.004 145/1999 (7.3) 149/2004 (7.4) 0.02
No 16/369 (4.3) 31/364 (8.5) 8/369 (2.2) 21/364 (5.8)
MRA
Yes 129/1694 (7.6) 107/1673 (6.4) 0.25 102/1694 (6.0) 113/1673 (6.8) 0.89
No 49/674 (7.3) 55/695 (7.9) 51/674 (7.6) 57/695 (8.2)
Digoxin
Yes 41/445 (9.2) 36/442 (8.1) 0.87 33/445 (7.4) 30/442 (6.8) 0.37
No 137/1923 (7.1) 126/1926 (6.5) 120/1923 (6.2) 140/1926 (7.3)
ARNI
Yes 27/250 (10.8) 31/258 (12.0) 0.38 25/250 (10.0) 25/258 (9.7) 0.59
No 151/2118 (7.1) 131/2110 (6.2) 128/2118 (6.0) 145/2110 (6.9)
Ivabradine
Yes 9/118 (7.6) 9/109 (8.3) 14/118 (11.9) 9/109 (8.3)
No 169/2250 (7.5) 153/2259 (6.8) 0.70 139/2250 (6.2) 161/2259 (7.1) 0.23
ACE-I/ARB target dose
<50% 89/1202 (7.4) 81/1228 (6.6) 0.32 59/1202 (4.9) 85/1228 (6.9) 0.01
>_50% 57/792 (7.2) 36/722 (5.0) 62/792 (7.8) 43/722 (6.0)
Beta-blocker target dose
<50% 78/1097 (7.1) 76/1108 (6.9) 0.54 64/1097 (5.8) 70/1108 (6.3) 0.69
>_50% 95/1177 (8.1) 80/1169 (6.8) 82/1177 (7.0) 96/1169 (8.2)
MRA target dose
<50% 12/215 (5.6) 21/200 (10.5) 0.01 10/215 (4.7) 10/200 (5.0) 0.92
>_50% 117/1479 (7.9) 86/1473 (5.8) 92/1479 (6.2) 103/1473 (7.0)
ICDa
Yes 60/621 (9.7) 61/619 (9.9) 0.43 44/621 (7.1) 63/619 (10.2) 0.09
No 118/1747 (6.8) 101/1749 (5.8) 109/1747 (6.2) 107/1749 (6.1)
CRTb
Yes 19/190 (10.0) 19/164 (11.6) 0.42 16/190 (8.4) 18/164 (11.0) 0.61
No 159/2178 (7.3) 143/2204 (6.5) 137/2178 (6.3) 152/2204 (6.9)
ACEi/ARB þ beta-blocker þ MRA
Yes 104/1399 (7.4) 72/1363 (6.5) 0.02 79/1399 (5.6) 88/1363 (6.5) 0.76
No 74/969 (7.6) 90/1005 (9.0) 74/969 (7.6) 82/1005 (8.2)
ACEi/ARB >_50% þ beta-blocker >_50%
Yes 45/521 (8.6) 22/451 (4.9) 0.03 43/521 (8.3) 26/451 (5.8) 0.03
No 133/1847 (7.2) 140/1917 (7.3) 110/1847 (6.0) 144/1917 (7.5)
ACEi/ARB >_50% þ beta-blocker >_50% þ MRA
Yes 39/371 (10.5) 11/339 (3.2) <0.001 30/371 (8.1) 19/339 (5.6) 0.07
No 139/1997 (7.0) 151/2029 (7.4) 123/1997 (6.2) 151/2029 (7.4)
ACEi/ARB >_50% þ beta-blocker >_50% þ ICDa
Yes 15/134 (11.2) 4/109 (3.7) 0.04 7/134 (5.2) 9/109 (8.3) 0.46
No 163/2234 (7.3) 158/2259 (7.0) 146/2234 (6.5) 161/2259 (7.1)
ARNI þ beta-blocker þ MRA
Yes 18/161 (11.2) 20/171 (11.7) 0.63 15/161 (9.3) 16/171 (9.4) 0.77
No 160/2207 (7.2) 142/2197 (6.5) 138/2207 (6.3) 154/2197 (7.0)
Data are presented as n/N (%). Safety population included all patients who had undergone randomization and received at least one dose of dapagliflozin (n= 2368) or placebo
(n= 2368).
ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; ARNI, angiotensin receptor neprilysin inhibitor; MRA, mineralocorticoid receptor antagonist; CRT,
cardiac resynchronization therapy; ICD, implantable cardioverter-defibrillator.
aEither implantable cardioverter-defibrillator or cardiac resynchronization therapy with a defibrillator.
bCardiac-resynchronization therapy with or without a defibrillator.
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